Episode 1, Part 3 of PharmTech AI Pulse Check covers why INTerpath-001's AI isn't ChatGPT and names pharma manufacturing's biggest AI governance gaps.
|Videos|April 19, 2023
Interview with LGM Pharma’s CEO, Prasad Raje
Author(s)LGM Pharma
Key Learning Objectives:
- LGM Pharma reports strong revenues in its first year of CDMO operations and continued growth in its API Sourcing business
- Offering API sourcing and CDMO services, plus Analytical Testing and new Drug Product R&D services, addresses the comprehensive needs of customers as LGM promotes its customer-centric strategies for growth.
- LGM Pharma elevated its API sourcing network with the 2020 acquisition of NexGen Pharma’s CDMO business – enabling the one company to provide comprehensive services.
Related to this article
Michael Levy, senior vice president, Digital & Innovation, USP, explains the digital supply chain in a preview of his upcoming CPHI Milan panel presentation, The Next Phase of Pharma Supply Chains.
FDA approves tavapadon, first D1/D5 agonist, validating AbbVie's $8.7B Cerevel deal and an October five-strength oral tablet launch.
Richard Jaenisch weighs how FDA's new NAM rule could reshape preclinical testing and what CMC teams should do now, on Manufacturing Intelligence.
In a preview of their panel discussion at AAPS PharmSci 360 2026, Alfred Rumondor, PhD, AbbVie, and Swita Singh, PhD, Bristol Myers Squibb, discuss the implementation of risk-based approaches for CMC.
Merck licenses SciBrunch's preclinical KRAS G12D inhibitor for $2.13B, raising tech transfer and scale-up questions for oral cancer drug development.
Ronald Piervincenzi, USP, urges drugmakers and purchasers to act on supply chain resilience to curb drug shortages and shape better policy.
Content on PharmTech.com this week ranged from fundamentals on the use of digital pathology in drug development, discussions on the use of AI in pharma, and regulatory actions impacting the industry.